The CRP drug results must not be good. The trial closed over a month ago but no announcement. One would think that if the APOCIII results were good they would announce them before the annual meeting on Tuesday. These delays have me concerned. Much is riding on the safety profile of these gen 2.0 drugs which are supposedly 10 times more potent than kynamaro.
At annual meeting they will get new options. The lower the stock price the lower the options pricing. I think we will see poor results on ISIS-CRP and ISIS-FGFR4Rx soon. All management signs point to such results but CRP was always a wild card. The rest of the year we ´ll see a lot of big news with much better results. ISIS-APOCIII, SMA, Factor XI, STAT3 are only a few of them.